Target intelligence / Profile preview

Long intergenic non-protein coding RNA 337 (ICMT-DT)

Target
ICMT-DT
Molecular classification
Long non-coding RNA (lncRNA), Divergent transcript
01

Overview

Long intergenic non-protein coding RNA 337 (ICMT-DT, also known as LINC00337) is a long non-coding RNA located on chromosome 1 (1p36.31), classified as a divergent transcript. It does not encode a protein, but regulates gene expression through molecular interactions such as sponging microRNAs. Its elevated expression has been linked to increased cell proliferation, migration, invasion, and chemoresistance in multiple cancers, including breast, pancreatic, and esophageal cancer. Mechanistically, ICMT-DT/LINC00337 acts via ceRNA functions—for example, it can sequester miR-145, impairing suppression of oncogenic targets like FSCN1, resulting in enhanced tumor progression. ICMT-DT is notable as a prognostic biomarker for malignancy, but is not a conventional therapeutic target like a receptor or enzyme, and there are no approved drugs that directly modulate its activity.

Other names
MGC40168C1orf211LINC00337NCRNA00337chromosome 1 open reading frame 211long intergenic non-protein coding RNA 337ICMT divergent transcriptnon-protein coding RNA 337
02

Mechanism of action

Acts as a competitive endogenous RNA (ceRNA) by sponging microRNAs (e.g., miR-145, impairing its suppression of target genes such as FSCN1, thus facilitating oncogenic pathways); Modulates tumor-associated macrophage polarization (M2 phenotype)

03

Biological functions

Regulation of gene expressionPromotion of cell proliferationModulation of cancer cell migration and invasionChemoresistance modulation
04

Disease associations

Cancer—promotes tumor progression (esophageal cancer, breast cancer, pancreatic ductal adenocarcinoma)Chemoresistance (notably to paclitaxel in breast cancer)
05

Safety considerations

None established for therapeutic intervention, as it is not a protein or established direct drug target; general safety concerns would relate to modulation of lncRNAs and cancer progression, but these are theoretical
06

Interacting drugs

Paclitaxel (evidence for chemoresistance; not a direct target but associated with resistance phenotype)
07

Biomarkers

High expression of LINC00337/ICMT-DT as a prognostic biomarker for poor cancer outcomes (e.g., esophageal and breast cancer)

Beyond the preview

Go deeper on Long intergenic non-protein coding RNA 337 (ICMT-DT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long intergenic non-protein coding RNA 337 (ICMT-DT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call